Royce M, Osgood CL, Amatya AK, Fiero MH, et al. FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer. Clin Cancer Res 2021 Dec 16. pii: 1078-0432.CCR-21-3247.
PMID: 34916216